1820. Clinical Characteristics of Invasive Extraintestinal Pathogenic Escherichia coli Disease Among Older Adult Patients Treated in Hospitals in the United States
Authors: Saade Elie , Geurtsen Jeroen , Baugh Bryan , Khoury Antoine El , Kalu Nnanya , Gauthier-Loiselle Marjolaine , Bungay Rebecca , Cloutier Martin , Pastor Luis Hernandez 
Published: December 2022

Background

The risk of invasive extraintestinal pathogenic Escherichia coli disease (IED) increases with age and can lead to severe outcomes, including sepsis and death.

Aim

To describe the clinical outcomes of IED in older adults in the United States (US).

Methods

The Premier Healthcare Database (10/01/2015-03/31/2020) was used to identify IED encounters among patients ≥ 60 years old. The index encounter was defined as the first encounter with a positive E. coli culture in a normally sterile body site (Group 1) or a positive E. coli culture in urine with signs of sepsis (Group 2), in the absence of other pathogens. Outcomes included medical resource utilization, antibiotic use, IED recurrence, and in-hospital death, and were descriptively reported during the index encounter and over the subsequent year.

Results

Overall, 19,773 patients with IED were included (mean age: 76.8 years; 67.4% female; 82.1% white). Approximately half of index encounters were from Group 1 (51.8%), and the vast majority of patients had community-onset IED (94.3%). Most index encounters led to inpatient hospitalization (96.5%; mean duration: 6.9 days) and 32.4% required transfer to an intensive care unit (mean duration: 3.7 days). During the index encounter, patients received a mean [SD] of 2.9 [1.4] antibiotic agents, and 30.1% received ≥ 4 agents. The 3 most prevalent antibiotics received were ceftriaxone (66.2%), vancomycin (36.3%), and piperacillin (35.0%; Fig 1). The majority of E. coli isolates showed resistance to ≥ 1 antibiotic category (61.7%), and 34.4% were classified as multi-drug resistant (i.e., ≥ 3 categories). Following discharge, 34.8% of patients were transferred to a skilled nursing/intermediate care facility. In-hospital death reached 6.8% during the index encounter and increased to 10.9% 1-year post-index (Fig 2). One-year post-index, 2.4% of patients had an IED recurrence and 36.8% were readmitted to the hospital for any reason (Fig 3).

Conclusion

Our findings suggest that IED is a severe disease that is associated with substantial burden and far-reaching consequences beyond the initial encounter. These findings emphasize the need for increased awareness and surveillance of IED and its consequences and the potential benefit of preventative measures.

Disclosures

Elie Saade, MD, Janssen: Grant/Research Support|Pfizer: Board Member|Pfizer: Grant/Research Support|Sanofi Pasteur: Grant/Research Support|Sanofi Pasteur: Speaking/lecture fees, travel reimbursement|Seqirus: Grant/Research Support Jeroen Geurtsen, PhD, Janssen: Employee of Janssen Vaccines & Prevention BV Bryan Baugh, MD, Janssen Research & Development LLC: Employee|Janssen Research & Development LLC: Stocks/Bonds Antoine El Khoury, PhD, Janssen: Employee of Janssen Global Services, LLC. Nnanya Kalu, PhD, Janssen: Employee of Janssen Scientific Affairs, LLC. Marjolaine Gauthier-Loiselle, PhD, Janssen: Advisor/Consultant|Janssen: Advisor/Consultant Rebecca Bungay, MScPH, Janssen: Employees of Analysis Group, Inc. which has received consultancy fees from Janssen Scientific Affairs, LLC for the conduct of this studies. Martin Cloutier, MSc, Janssen: Employees of Analysis Group, Inc. which has received consultancy fees from Janssen Scientific Affairs, LLC for the conduct of this studies. Luis Hernandez Pastor, PharmD, PhD, Janssen: Employee of Janssen Pharmaceutica NV.